Establishment Labs Announces National Medical Products Administration Approval For Motiva Implants In China
Portfolio Pulse from Benzinga Newsdesk
Establishment Labs Holdings Inc. (NASDAQ:ESTA) has received approval from China's National Medical Products Administration for its Motiva Implants. This marks the company's entry into the second largest global market for breast aesthetics. The approval is the first for breast implant technology in China in over a decade. The company expects Chinese plastic surgeons to adopt their technology as their first choice.
November 09, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Establishment Labs' approval for Motiva Implants in China could potentially boost the company's market share and revenues. The approval is the first for breast implant technology in China in over a decade, indicating a significant opportunity for the company.
The approval of Motiva Implants in China, the second largest global market for breast aesthetics, presents a significant opportunity for Establishment Labs. Given that this is the first approval for breast implant technology in China in over a decade, it is likely that the company will see increased adoption of its product, potentially leading to increased market share and revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100